ipilimumab,nivolumab,durvalumab,vinorelbine,paclitaxel,carboplatin,cisplatin,gemcitabine,docetaxel,pemetrexed
bms,astrazeneca
['durva', 'aegean']
overall, aegean impressive: clear pcr benefit with addition of durvalumab to 4 cycles of chemotherapy and encouraging efs rates. contribution of adjuvant component remains unclear and won't be answered by this wave of studies but an immediate new standard once approved. #aacr23 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown, Co-Host Official @IASLC Podcast #ITYSL #HereWeGo